ESC 365 - Benefits and risks of longer-than-1-year dual antiplatelet therapy in TWLIGHT-like patients with high risk of ischemic or bleeding events after drug-eluting stents implantation

ESC Premium Access

Benefits and risks of longer-than-1-year dual antiplatelet therapy in TWLIGHT-like patients with high risk of ischemic or bleeding events after drug-eluting stents implantation

Session: Interventions in Coronary Artery Disease

Topic: Epidemiology, Prognosis, Outcome

Speaker: Doctor H. Wang (Beijing, CN)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Doctor Haoyu Wang

Fuwai Hospital, CAMS and PUMC, Beijing (China)

0 follower

4 more presentations in this session

Managed care improves prognosis in acute myocardial infarction survivors. Data from the MAnaged Care for Acute Myocardial Infarction Survivors (MACAMIS) Programme.

Speaker: Professor P. Jankowski (Warsaw, PL)

Systematic review and meta-analysis of placebo-controlled invasive interventions for the management of chronic stable angina

Speaker: Doctor M. Rivera (St Louis, US)

Quantitative flow ratio to predict non-target-vessel-related events at 5 years in STEMI patients undergoing angiography-guided revascularization

Speaker: Doctor S. Baer (Turku, FI)

Risk stratification based on academic research consortium high bleeding risk criteria for long-term bleeding event after everolimus-eluting stent implantation

Speaker: Doctor K. Miura (Kurashiki, JP)

Access the full session

Interventions in Coronary Artery Disease

Speakers: Doctor H. Wang, Professor P. Jankowski, Doctor M. Rivera, Doctor S. Baer, Doctor K. Miura

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources